Antonio C. Wolff
#139,363
Most Influential Person Now
Researcher
Antonio C. Wolff's AcademicInfluence.com Rankings
Antonio C. Wolffengineering Degrees
Engineering
#5138
World Rank
#6382
Historical Rank
Electrical Engineering
#1393
World Rank
#1486
Historical Rank
Antonio C. Wolffcomputer-science Degrees
Computer Science
#6592
World Rank
#6950
Historical Rank
Computational Linguistics
#1172
World Rank
#1186
Historical Rank
Machine Learning
#2195
World Rank
#2223
Historical Rank
Artificial Intelligence
#2462
World Rank
#2503
Historical Rank
Download Badge
Engineering Computer Science
Antonio C. Wolff's Degrees
- PhD Computer Science Stanford University
- Masters Electrical Engineering University of California, Berkeley
Similar Degrees You Can Earn
Why Is Antonio C. Wolff Influential?
(Suggest an Edit or Addition)Antonio C. Wolff's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. (2006) (3857)
- American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. (2010) (3403)
- Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. (2014) (3308)
- American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. (2005) (1736)
- 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. (2006) (1563)
- Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. (2013) (1551)
- American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. (2007) (1419)
- American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. (2002) (1006)
- Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. (2014) (1004)
- Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. (2018) (926)
- Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. (2018) (887)
- American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). (2010) (760)
- Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus: a systematic review and meta-analysis. (2008) (746)
- Weekly paclitaxel in the adjuvant treatment of breast cancer. (2008) (673)
- American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. (2010) (668)
- American Society of Clinical Oncology 2006 update of the breast cancer follow-up and management guidelines in the adjuvant setting. (2006) (527)
- Breast cancer follow-up and management after primary treatment: American Society of Clinical Oncology clinical practice guideline update. (2013) (513)
- Breast cancer. Clinical practice guidelines in oncology. (2009) (498)
- Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer. (2015) (483)
- Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. (2008) (481)
- TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer. (2012) (430)
- Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update. (2020) (423)
- Diabetes mellitus and breast cancer outcomes: a systematic review and meta-analysis. (2011) (359)
- Detection of Cancer DNA in Plasma of Patients with Early-Stage Breast Cancer (2014) (328)
- Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial. (2016) (317)
- Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update. (2017) (311)
- Detection of Tumor PIK3CA Status in Metastatic Breast Cancer Using Peripheral Blood (2012) (305)
- American society of clinical oncology/college of american pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. (2010) (292)
- Randomized phase III placebo-controlled trial of letrozole plus oral temsirolimus as first-line endocrine therapy in postmenopausal women with locally advanced or metastatic breast cancer. (2013) (266)
- Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years. (2016) (261)
- Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: ASCO Clinical Practice Guideline Update-Integration of Results From TAILORx. (2019) (227)
- Transitioning to Breast Cancer Survivorship: Perspectives of Patients, Cancer Specialists, and Primary Care Providers (2009) (220)
- Adjuvant chemotherapy in older women with early-stage breast cancer. (2009) (220)
- Timed sequential treatment with cyclophosphamide, doxorubicin, and an allogeneic granulocyte-macrophage colony-stimulating factor-secreting breast tumor vaccine: a chemotherapy dose-ranging factorial study of safety and immune activation. (2009) (214)
- TBCRC 022: A Phase II Trial of Neratinib and Capecitabine for Patients With Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer and Brain Metastases (2019) (213)
- HER2 testing in breast cancer: NCCN Task Force report and recommendations. (2006) (205)
- Breast cancer, version 3.2013: featured updates to the NCCN guidelines. (2015) (204)
- Obesity at diagnosis is associated with inferior outcomes in hormone receptor‐positive operable breast cancer (2012) (197)
- Breast Cancer, Version 3.2013 (2013) (193)
- Past, present, and future challenges in breast cancer treatment. (2014) (191)
- Genome-wide methylation analysis identifies genes specific to breast cancer hormone receptor status and risk of recurrence. (2011) (189)
- Treatment of HER2-positive breast cancer. (2014) (189)
- Elevated tissue sodium concentration in malignant breast lesions detected with non-invasive 23Na MRI (2007) (182)
- Breast cancer version 3.2014. (2014) (180)
- TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes. (2020) (167)
- The NCCN. Invasive breast cancer: Clinical practice guidelines in oncology™ (2007) (165)
- Evaluation of alternate size descriptors for dose calculation of anticancer drugs in the obese. (2007) (157)
- Seven-Year Follow-Up Analysis of Adjuvant Paclitaxel and Trastuzumab Trial for Node-Negative, Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer. (2019) (156)
- Systematic Review: Gene Expression Profiling Assays in Early-Stage Breast Cancer (2008) (155)
- Long-Term Follow-Up of the E1199 Phase III Trial Evaluating the Role of Taxane and Schedule in Operable Breast Cancer. (2015) (155)
- Prevention, screening, and surveillance care for breast cancer survivors compared with controls: changes from 1998 to 2002. (2009) (152)
- NCCN Task Force Report: Adjuvant Therapy for Breast Cancer. (2006) (147)
- Long term side effects of adjuvant chemotherapy in patients with early breast cancer. (2015) (144)
- Postoperative Mortality in Cancer Patients With Preexisting Diabetes (2010) (144)
- Novel methylated biomarkers and a robust assay to detect circulating tumor DNA in metastatic breast cancer. (2014) (140)
- NCCN Task Force Report: Estrogen Receptor and Progesterone Receptor Testing in Breast Cancer by Immunohistochemistry. (2009) (139)
- Comparing Care for Breast Cancer Survivors to Non-Cancer Controls: A Five-Year Longitudinal Study (2009) (138)
- Association of Circulating Tumor Cells With Late Recurrence of Estrogen Receptor–Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial (2018) (134)
- Estrogen and Progesterone Receptor Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Guideline Update. (2020) (134)
- Colorectal Cancer Outcomes, Recurrence, and Complications in Persons With and Without Diabetes Mellitus: A Systematic Review and Meta-Analysis (2010) (133)
- Invasive breast cancer. (2011) (133)
- Translational Breast Cancer Research Consortium (TBCRC) 022: A Phase II Trial of Neratinib for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases. (2016) (130)
- NCCN Practice Guidelines for Breast Cancer. (2000) (129)
- Comparative Pharmacokinetics of Weekly and Every-Three-Weeks Docetaxel (2004) (126)
- Phase II trial of doxorubicin and paclitaxel plus granulocyte colony-stimulating factor in metastatic breast cancer: an Eastern Cooperative Oncology Group Study. (1999) (126)
- Clinical Notice for American Society of Clinical Oncology-College of American Pathologists guideline recommendations on ER/PgR and HER2 testing in breast cancer. (2011) (122)
- The Role of Informatics in Promoting Patient-Centered Care (2011) (122)
- Metastatic breast cancer, version 1.2012: featured updates to the NCCN guidelines. (2012) (120)
- Adherence and persistence with oral adjuvant chemotherapy in older women with early-stage breast cancer in CALGB 49907: adherence companion study 60104. (2010) (112)
- Feasibility and value of PatientViewpoint: a web system for patient‐reported outcomes assessment in clinical practice (2013) (112)
- Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer: ASCO Clinical Practice Guideline Focused Update. (2018) (111)
- Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study. (2021) (108)
- Selection of Optimal Adjuvant Chemotherapy Regimens for Human Epidermal Growth Factor Receptor 2 (HER2) -Negative and Adjuvant Targeted Therapy for HER2-Positive Breast Cancers: An American Society of Clinical Oncology Guideline Adaptation of the Cancer Care Ontario Clinical Practice Guideline. (2016) (104)
- Combination Epigenetic Therapy in Advanced Breast Cancer with 5-Azacitidine and Entinostat: A Phase II National Cancer Institute/Stand Up to Cancer Study (2016) (99)
- Impact of Diabetes, Insulin, and Metformin Use on the Outcome of Patients With Human Epidermal Growth Factor Receptor 2-Positive Primary Breast Cancer: Analysis From the ALTTO Phase III Randomized Trial. (2017) (99)
- Asking the right questions: investigating needs assessments and health-related quality-of-life questionnaires for use in oncology clinical practice (2007) (97)
- The phosphoinositide-3-kinase-Akt-mTOR pathway as a therapeutic target in breast cancer. (2013) (95)
- Risk of marrow neoplasms after adjuvant breast cancer therapy: the national comprehensive cancer network experience. (2015) (92)
- A Phase II study of the polyamine analog N1,N11-diethylnorspermine (DENSpm) daily for five days every 21 days in patients with previously treated metastatic breast cancer. (2003) (92)
- Monitoring of Serum DNA Methylation as an Early Independent Marker of Response and Survival in Metastatic Breast Cancer: TBCRC 005 Prospective Biomarker Study. (2017) (90)
- Older Adults’ Views and Communication Preferences About Cancer Screening Cessation (2017) (90)
- Randomized Phase II Trial of Fulvestrant Plus Everolimus or Placebo in Postmenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer Resistant to Aromatase Inhibitor Therapy: Results of PrE0102. (2018) (89)
- Neuropathy is not associated with clinical outcomes in patients receiving adjuvant taxane-containing therapy for operable breast cancer. (2012) (88)
- Tumor targeting by conjugation of DHA to paclitaxel. (2001) (87)
- Race and hormone receptor-positive breast cancer outcomes in a randomized chemotherapy trial. (2012) (86)
- HER2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update Summary. (2018) (84)
- Impact of gene expression profiling tests on breast cancer outcomes. (2007) (83)
- HER2-enriched subtype and ERBB2 expression in HER2-positive breast cancer treated with dual HER2 blockade. (2019) (83)
- Phase I study of docosahexaenoic acid-paclitaxel: a taxane-fatty acid conjugate with a unique pharmacology and toxicity profile. (2003) (82)
- Adjuvant Paclitaxel and Trastuzumab for Node-Negative, HER2-Positive Breast Cancer. (2023) (80)
- Quality of care for comorbid conditions during the transition to survivorship: differences between cancer survivors and noncancer controls. (2013) (76)
- Phase I trial of pegylated liposomal doxorubicin and docetaxel in advanced breast cancer. (2001) (75)
- Significance of Circulating Tumor Cells in Metastatic Triple-Negative Breast Cancer Patients within a Randomized, Phase II Trial: TBCRC 019 (2015) (73)
- TBCRC 031: Randomized Phase II Study of Neoadjuvant Cisplatin Versus Doxorubicin-Cyclophosphamide in Germline BRCA Carriers With HER2-Negative Breast Cancer (the INFORM trial). (2020) (72)
- Monitoring of neoadjuvant chemotherapy using multiparametric, 23Na sodium MR, and multimodality (PET/CT/MRI) imaging in locally advanced breast cancer (2011) (72)
- Treatment of HER 2-positive Breast Cancer (2015) (71)
- Comparison of breast cancer recurrence risk and cardiovascular disease incidence risk among postmenopausal women with breast cancer (2012) (71)
- A Randomized Phase II Feasibility Trial of BMS-275291 in Patients with Early Stage Breast Cancer (2004) (68)
- A Feasibility Study of Cyclophosphamide, Trastuzumab, and an Allogeneic GM-CSF–Secreting Breast Tumor Vaccine for HER2+ Metastatic Breast Cancer (2014) (67)
- Research issues affecting preoperative systemic therapy for operable breast cancer. (2008) (66)
- Factors affecting pharmacokinetic variability following doxorubicin and docetaxel-based therapy. (2004) (65)
- A Phase II Randomized Study of Neoadjuvant Letrozole Plus Alpelisib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer (NEO-ORB) (2019) (65)
- TBCRC 032 IB/II Multicenter Study: Molecular Insights to AR Antagonist and PI3K Inhibitor Efficacy in Patients with AR+ Metastatic Triple-Negative Breast Cancer (2019) (64)
- Systemic therapy. (2002) (63)
- Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancer (2018) (63)
- Cardiac Outcomes of Patients Receiving Adjuvant Weekly Paclitaxel and Trastuzumab for Node-Negative, ERBB2-Positive Breast Cancer. (2016) (61)
- Does pre-existing diabetes affect prostate cancer prognosis? A systematic review (2010) (61)
- Invasive breast cancer. (2007) (60)
- Adjuvant Anti-HER2 Therapy, Treatment-Related Amenorrhea, and Survival in Premenopausal HER2-Positive Early Breast Cancer Patients (2018) (59)
- Chemotherapy-related amenorrhea after adjuvant paclitaxel–trastuzumab (APT trial) (2015) (59)
- TBCRC 008: Early Change in 18F-FDG Uptake on PET Predicts Response to Preoperative Systemic Therapy in Human Epidermal Growth Factor Receptor 2–Negative Primary Operable Breast Cancer (2015) (58)
- A short-term biomarker modulation study of simvastatin in women at increased risk of a new breast cancer (2012) (58)
- Symptoms, supportive care needs, and function in cancer patients: how are they related? (2008) (58)
- Personalized Medicine in the Oncology Clinic: Implementation and Outcomes of the Johns Hopkins Molecular Tumor Board. (2017) (58)
- A prospective analysis of surgery and survival in stage IV breast cancer (TBCRC 013). (2016) (57)
- TBCRC 018: phase II study of iniparib in combination with irinotecan to treat progressive triple negative breast cancer brain metastases (2014) (55)
- A Validated Model for Identifying Patients Unlikely to Benefit From the 21-Gene Recurrence Score Assay. (2015) (55)
- Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer: ASCO Guideline Update (2022) (55)
- Predicting Cancer Therapy-Induced Cardiotoxicity (2002) (55)
- Disposition of docosahexaenoic acid-paclitaxel, a novel taxane, in blood: in vitro and clinical pharmacokinetic studies. (2003) (55)
- Preoperative therapy in breast cancer: lessons from the treatment of locally advanced disease. (2002) (54)
- Needs assessments can identify scores on HRQOL questionnaires that represent problems for patients: an illustration with the Supportive Care Needs Survey and the QLQ-C30 (2010) (54)
- Primary systemic therapy in operable breast cancer. (2000) (52)
- Intensive dose-dense compared with high-dose adjuvant chemotherapy for high-risk operable breast cancer: Southwest Oncology Group/Intergroup study 9623. (2007) (51)
- Optimizing the Use of Gene Expression Profiling in Early-Stage Breast Cancer. (2016) (51)
- Functional Decline and Resilience in Older Women Receiving Adjuvant Chemotherapy for Breast Cancer (2019) (50)
- Individualized Molecular Analyses Guide Efforts (IMAGE): A Prospective Study of Molecular Profiling of Tissue and Blood in Metastatic Triple-Negative Breast Cancer (2016) (49)
- TBCRC 019: A Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel with or without the Anti-Death Receptor 5 Monoclonal Antibody Tigatuzumab in Patients with Triple-Negative Breast Cancer (2015) (48)
- Randomized Phase III Postoperative Trial of Platinum-Based Chemotherapy Versus Capecitabine in Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy: ECOG-ACRIN EA1131 (2021) (47)
- Seven-year (yr) follow-up of adjuvant paclitaxel (T) and trastuzumab (H) (APT trial) for node-negative, HER2-positive breast cancer (BC). (2017) (45)
- Therapeutic options in the management of metastatic breast cancer. (2008) (45)
- Multiparametric and Multinuclear Magnetic Resonance Imaging of Human Breast Cancer: Current Applications (2004) (43)
- Multiparametric magnetic resonance imaging, spectroscopy and multinuclear (²³Na) imaging monitoring of preoperative chemotherapy for locally advanced breast cancer. (2010) (42)
- Randomized Trial of Standard Adjuvant Chemotherapy Regimens Versus Capecitabine in Older Women With Early Breast Cancer: 10-Year Update of the CALGB 49907 Trial. (2019) (42)
- Concordance of cancer patients’ function, symptoms, and supportive care needs (2009) (41)
- Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical Trial (2021) (41)
- Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer: ASCO Guideline Update. (2020) (40)
- Racial disparities in the rate of cardiotoxicity of HER2‐targeted therapies among women with early breast cancer (2018) (40)
- Comorbid condition care quality in cancer survivors: role of primary care and specialty providers and care coordination (2015) (40)
- A phase I vaccine safety and chemotherapy dose-finding trial of an allogeneic GM-CSF-secreting breast cancer vaccine given in a specifically timed sequence with immunomodulatory doses of cyclophosphamide and doxorubicin. (2004) (39)
- Phase III study of doxorubicin-cyclophosphamide followed by paclitaxel or docetaxel given every 3 weeks or weekly in operable breast cancer: Results of Intergroup Trial E1199 (2007) (38)
- Abstract S1-02: PrECOG 0102: A randomized, double-blind, phase II trial of fulvestrant plus everolimus or placebo in post-menopausal women with hormone receptor (HR)-positive, HER2-negative metastatic breast cancer (MBC) resistant to aromatase inhibitor (AI) therapy (2017) (38)
- TBCRC 048: A phase II study of olaparib monotherapy in metastatic breast cancer patients with germline or somatic mutations in DNA damage response (DDR) pathway genes (Olaparib Expanded). (2020) (38)
- It’s who you know: patient-sharing, quality, and costs of cancer survivorship care (2014) (37)
- Functional Impairment of Human Resident Cardiac Stem Cells by the Cardiotoxic Antineoplastic Agent Trastuzumab (2012) (37)
- Abstract S1-04: A phase II study of adjuvant paclitaxel (T) and trastuzumab (H) (APT trial) for node-negative, HER2-positive breast cancer (BC) (2013) (36)
- Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03) (2021) (34)
- Phase II study of ifosfamide, carboplatin, and oral etoposide chemotherapy for extensive-disease small-cell lung cancer: an Eastern Cooperative Oncology Group pilot study. (1995) (34)
- Improving an electronic system for measuring PROs in routine oncology practice (2015) (34)
- TBCRC 022: Phase II trial of neratinib + capecitabine for patients (Pts) with human epidermal growth factor receptor 2 (HER2+) breast cancer brain metastases (BCBM). (2017) (34)
- Phase II Study of Lapatinib in Combination With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: Clinical Outcomes and Predictive Value of Early [18F]Fluorodeoxyglucose Positron Emission Tomography Imaging (TBCRC 003). (2015) (34)
- TBCRC 030: A phase II study of preoperative cisplatin vs. paclitaxel in triple-negative breast cancer: evaluating the homologous recombination deficiency (HRD) biomarker. (2020) (33)
- A combinatorial biomarker predicts pathologic complete response to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2+ breast cancer. (2019) (33)
- Management of Breast Cancer During the COVID-19 Pandemic: A Stage- and Subtype-Specific Approach. (2020) (33)
- Tumor Marker Usage and Medical Care Costs among Older Early-Stage Breast Cancer Survivors (2015) (33)
- Effect of Pretreatment Renal Function on Treatment and Clinical Outcomes in the Adjuvant Treatment of Older Women With Breast Cancer: Alliance A171201, an Ancillary Study of CALGB/CTSU 49907. (2016) (31)
- Intensive Weight Loss Intervention and Cancer Risk in Adults with Type 2 Diabetes: Analysis of the Look AHEAD Randomized Clinical Trial (2020) (31)
- Quality of end-of-life care for patients with advanced cancer in an academic medical center. (2011) (29)
- TBCRC026: Phase II Trial Correlating Standardized Uptake Value With Pathologic Complete Response to Pertuzumab and Trastuzumab in Breast Cancer. (2019) (29)
- Changes in Breast Density and Circulating Estrogens in Postmenopausal Women Receiving Adjuvant Anastrozole (2011) (28)
- Older Adults’ Preferences for Discussing Long-Term Life Expectancy: Results From a National Survey (2018) (27)
- Comparison of Changes in the Lipid Profile of Postmenopausal Women With Early Stage Breast Cancer Treated With Exemestane or Letrozole (2012) (27)
- Dissecting the effect of hormone receptor status in patients with HER2-positive early breast cancer: exploratory analysis from the ALTTO (BIG 2-06) randomized clinical trial (2019) (27)
- Pathologic complete response in breast cancer patients receiving anthracycline‐ and taxane‐based neoadjuvant chemotherapy (2010) (27)
- Multiparametric Whole-body MRI with Diffusion-weighted Imaging and ADC Mapping for the Identification of Visceral and Osseous Metastases From Solid Tumors. (2018) (27)
- Abstract S6-02: TBCRC023: A randomized multicenter phase II neoadjuvant trial of lapatinib plus trastuzumab, with endcorine therapy and without chemotherapy, for 12 vs. 24 weeks in patients with HER2 overexpressing breast cancer (2015) (26)
- Abstract GS1-05: TBCRC 033: A randomized phase II study of adjuvant trastuzumab emtansine (T-DM1) vs paclitaxel (T) in combination with trastuzumab (H) for stage I HER2-positive breast cancer (BC) (ATEMPT) (2020) (26)
- Phase II trial of pegylated liposomal doxorubicin plus docetaxel with and without trastuzumab in metastatic breast cancer: Eastern Cooperative Oncology Group Trial E3198 (2010) (26)
- Young age at diagnosis is associated with worse prognosis in the Luminal A breast cancer subtype: a retrospective institutional cohort study (2018) (26)
- Evaluation of the Predictive Role of Tumor Immune Infiltrate in Patients with HER2-Positive Breast Cancer Treated with Neoadjuvant Anti-HER2 Therapy without Chemotherapy (2019) (25)
- E2112: Randomized Phase III Trial of Endocrine Therapy Plus Entinostat or Placebo in Hormone Receptor–Positive Advanced Breast Cancer. A Trial of the ECOG-ACRIN Cancer Research Group (2021) (25)
- CDK4 and CDK6 Inhibition in Breast Cancer - A New Standard. (2016) (25)
- TBCRC023: A Randomized Phase II Neoadjuvant Trial of Lapatinib Plus Trastuzumab Without Chemotherapy for 12 versus 24 Weeks in Patients with HER2-Positive Breast Cancer (2019) (25)
- The impact of sharing results of a randomized breast cancer clinical trial with study participants (2009) (24)
- Liposomal anthracyclines and new treatment approaches for breast cancer. (2003) (23)
- Local–regional recurrence in women with small node-negative, HER2-positive breast cancer: results from a prospective multi-institutional study (the APT trial) (2019) (23)
- Acute myeloid leukemia and myelodysplastic syndrome after adjuvant chemotherapy: A population‐based study among older breast cancer patients (2018) (23)
- Estrogen receptor: a never ending story? (2011) (22)
- Enhancing therapeutic decision making when options abound: toxicities matter. (2014) (22)
- Analysis of regional timelines to set up a global phase III clinical trial in breast cancer: the adjuvant lapatinib and/or trastuzumab treatment optimization experience. (2013) (22)
- Lapatinib-Related Rash and Breast Cancer Outcome in the ALTTO Phase III Randomized Trial. (2016) (22)
- Preferred Clinician Communication About Stopping Cancer Screening Among Older US Adults: Results From a National Survey (2018) (22)
- Reply to E.A. Rakha et al. (2015) (21)
- Troponins for predicting cardiotoxicity from cancer therapy (2000) (21)
- Evaluating information prescriptions in two clinical environments. (2011) (20)
- The Adjuvant Treatment of HER2-Positive Breast Cancer (2012) (20)
- In reply [3] (2007) (19)
- Myeloid toxicity in breast cancer patients receiving adjuvant chemotherapy with pegfilgrastim support. (2006) (19)
- DNA Methylation Markers for Breast Cancer Detection in the Developing World (2019) (18)
- Sharing in care: engaging care partners in the care and communication of breast cancer patients (2019) (18)
- A randomized trial (MA.17R) of extending adjuvant letrozole for 5 years after completing an initial 5 years of aromatase inhibitor therapy alone or preceded by tamoxifen in postmenopausal women with early-stage breast cancer. (2016) (18)
- With maturity comes confidence: EBCTCG tamoxifen update (2011) (18)
- Docetaxel metabolism is not altered by imatinib: findings from an early phase study in metastatic breast cancer (2011) (18)
- Re: predictability of adjuvant trastuzumab benefit in N9831 patients using the ASCO/CAP HER2-positivity criteria. (2012) (17)
- Adjuvant chemotherapy for postmenopausal lymph node-negative breast cancer: it ain't necessarily so. (2002) (17)
- Do Breast Cancer Cell Lines Provide a Relevant Model of the Patient Tumor Methylome? (2014) (16)
- Demographic, health, and attitudinal factors predictive of cancer screening decisions in older adults (2019) (16)
- The androgen receptor in breast cancer: learning from the past (2010) (16)
- Regional Nodal Irradiation After Breast Conserving Surgery for Early HER2-Positive Breast Cancer: Results of a Subanalysis From the ALTTO Trial (2017) (16)
- A feasibility study of combination therapy with trastuzumab (T), cyclophosphamide (CY), and an allogeneic GM-CSF-secreting breast tumor vaccine for the treatment of HER2+ metastatic breast cancer. (2011) (16)
- Multiparametric and Multimodality Functional Radiological Imaging for Breast Cancer Diagnosis and Early Treatment Response Assessment. (2015) (16)
- African American women who receive primary anthracycline- and taxane-based chemotherapy for triple-negative breast cancer suffer worse outcomes compared with white women. (2009) (15)
- Fixed-dose capecitabine is feasible: results from a pharmacokinetic and pharmacogenetic study in metastatic breast cancer (2013) (15)
- A Phase II Study of the Polyamine Analog N 1 , N 11-Diethylnorspermine ( DENSpm ) Daily for Five Days Every 21 Days in Patients with Previously Treated Metastatic Breast Cancer (2003) (15)
- A PIK3CA mutation detected in plasma from a patient with synchronous primary breast and lung cancers. (2014) (15)
- Randomized Phase II Trial of Fulvestrant Plus Everolimus or Placebo in Postmenopausal Women With Hormone Receptor – Positive , Human Epidermal Growth Factor Receptor 2 – Negative Metastatic Breast Cancer Resistant to Aromatase Inhibitor Therapy : Results of PrE 0102 (2018) (15)
- Comparison of breast cancer risk in women with and without systemic lupus erythematosus in a Medicare population (2015) (15)
- A randomized intervention involving family to improve communication in breast cancer care (2021) (15)
- Pre- and Postoperative Neratinib for HER2-Positive Breast Cancer Brain Metastases: Translational Breast Cancer Research Consortium 022. (2020) (15)
- Older Adults’ Preferences for When and How to Discuss Life Expectancy in Primary Care (2017) (15)
- A phase II pharmacokinetic/pharmacogenetic (PK/PG) study using fixed-dose capecitabine in metastatic breast cancer (MBC). (2011) (15)
- Abstract GS6-03: Circulating tumor cells (CTCs) five years after diagnosis are prognostic for late recurrence in operable stage II-III breast cancer (2018) (14)
- Social support and its implications in older, early‐stage breast cancer patients in CALGB 49907 (Alliance A171301) (2016) (14)
- First international TNBC conference meeting report (2018) (14)
- HER2-enriched subtype and ERBB2 mRNA as predictors of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer: A combined analysis of TBCRC006/023 and PAMELA trials. (2018) (14)
- Breast Cancer (2023) (14)
- Pathologic complete response to preoperative sequential doxorubicin/cyclophosphamide and single-agent taxane with or without trastuzumab in stage II/III HER2-positive breast cancer. (2010) (13)
- Evolving Role of the Estrogen Receptor as a Predictive Biomarker: ESR1 Mutational Status and Endocrine Resistance in Breast Cancer. (2016) (13)
- A phase II study evaluating the efficacy of zoledronic acid in prevention of aromatase inhibitor-associated musculoskeletal symptoms: the ZAP trial (2018) (13)
- The Clinical Benefit of Pegylated Liposomal Doxorubicin in Patients With Metastatic Breast Cancer Previously Treated With Conventional Anthracyclines: A Multicentre Phase II Trial (2007) (13)
- Development of a biomimetic peptide derived from collagen IV with anti-angiogenic activity in breast cancer (2011) (13)
- Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer-Clinical Notice (2010) (13)
- TBCRC 022: Phase II trial of neratinib for patients (Pts) with human epidermal growth factor receptor 2 (HER2+) breast cancer and brain metastases (BCBM). (2014) (12)
- Luteinizing hormone-releasing hormone agonists in premenopausal hormone receptor-positive breast cancer. (2007) (12)
- JNCCN HER 2 Testing in Breast Cancer : NCCN Task Force Report and Recommendations (2006) (12)
- Pharmacokinetic (PK) analyses in CSF and plasma from TBCRC049, an ongoing trial to assess the safety and efficacy of the combination of tucatinib, trastuzumab and capecitabine for the treatment of leptomeningeal metastasis (LM) in HER2 positive breast cancer. (2021) (12)
- Implementing a breast cancer registry and treatment plan/summary program in clinical practice: A pilot program (2013) (12)
- Reply to G. Sauter et al. (2009) (12)
- Abstract P2-18-09: TBCRC 013: A prospective analysis of the role of surgery in stage IV breast cancer (2013) (12)
- Toronto Workshop on Late Recurrence in Estrogen Receptor–Positive Breast Cancer: Part 1: Late Recurrence: Current Understanding, Clinical Considerations (2019) (12)
- Feasibility trial of partial breast irradiation with concurrent dose-dense doxorubicin and cyclophosphamide in early-stage breast cancer. (2009) (12)
- Cardiac safety of trastuzumab (H) in combination with pegylated liposomal doxorubicin (D) and docetaxel (T) in HER2-positive metastatic breast cancer (MBC): preliminary results of the Eastern Cooperative Oncology Group Trial E3198 (Abstract) (2003) (12)
- TBCRC 030: A randomized phase II study of preoperative cisplatin versus paclitaxel in TNBC—Evaluating the homologous recombination deficiency (HRD) biomarker. (2019) (11)
- Abstract 4666: A phase 2 study investigating the safety, efficacy and surrogate biomarkers of response of 5-azacitidine (5-AZA) andentinostat (MS-275) in patients with triple-negative advanced breast cancer. (2013) (11)
- TBCRC 003: Phase II trial of trastuzumab (T) and lapatinib (L) in patients (pts) with HER2+ metastatic breast cancer (MBC). (2010) (11)
- In vitro and In vivo Clinical Pharmacology of Dimethyl Benzoylphenylurea, a Novel Oral Tubulin-Interactive Agent (2005) (11)
- Updated Results of TBCRC026: Phase II Trial Correlating Standardized Uptake Value With Pathological Complete Response to Pertuzumab and Trastuzumab in Breast Cancer (2021) (10)
- Single-agent topotecan as first-line chemotherapy in women with metastatic breast cancer: final results of eastern cooperative oncology group trial E8193. (2005) (10)
- ERBB2-Low Breast Cancer-Is It a Fact or Fiction, and Do We Have the Right Assay? (2022) (10)
- The Effects of a Remote-based Weight Loss Program on Adipocytokines, Metabolic Markers, and Telomere Length in Breast Cancer Survivors: the POWER-Remote Trial (2020) (10)
- Clinical Practice Guidelines in Oncology: Translating Evidence Into Practice (and back). (2005) (10)
- Phase II trial of the dual IGF-1R/IR inhibitor BMS-754807 with or without letrozole in aromatase inhibitor-resistant breast cancer. (2011) (10)
- A multi-institutional double-blind phase II study evaluating response and surrogate biomarkers to carboplatin and nab-paclitaxel (CP) with or without vorinostat as preoperative systemic therapy (PST) in HER2-negative primary operable breast cancer (TBCRC008). (2010) (10)
- The role of ovarian ablation in the adjuvant therapy of breast cancer (2008) (10)
- Coordination of care in breast cancer survivors: an overview. (2011) (10)
- Still waiting after 110 years: the optimal use of ovarian ablation as adjuvant therapy for breast cancer. (2006) (9)
- Patient perspectives on chemotherapy de‐escalation in breast cancer (2021) (9)
- Abstract S2-1: Obesity at Diagnosis Is Associated with Inferior Outcomes in Hormone Receptor Positive Breast Cancer (2010) (9)
- Implications of Neoadjuvant Therapy in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer. (2019) (9)
- Use of SERMs for the Adjuvant Therapy of Early‐Stage Breast Cancer (2001) (9)
- Chemotherapy-related amenorrhea (CRA) after adjuvant ado-trastuzumab emtansine (T-DM1) compared to paclitaxel in combination with trastuzumab (TH) (TBCRC033: ATEMPT Trial) (2021) (9)
- Abstract P6-15-02: A Phase Ib Study Evaluating Safety, Tolerability, Pharmacokinetics (PK), and Activity of the Phosphoinositide-3 Kinase (PI3K) Inhibitor GDC-0941 in Combination with Trastuzumab-MCC-DM1 (T-DM1) in Patients with Advanced HER2-Positive Breast Cancer (2010) (9)
- Preoperative Breast MRI for Newly Diagnosed Ductal Carcinoma in Situ: Imaging Features and Performance in a Multicenter Setting (ECOG-ACRIN E4112 Trial). (2021) (9)
- Toronto Workshop on Late Recurrence in Estrogen Receptor-Positive Breast Cancer: Part 2: Approaches to Predict and Identify Late Recurrence, Research Directions (2019) (9)
- Breast cancer: noninvasive and special situations. (2010) (9)
- Insights on adjuvant endocrine therapy for premenopausal and postmenopausal breast cancer (2007) (8)
- Multiparametric Magnetic Resonance Imaging, Spectroscopy and Multinuclear ( 23 Na) Imaging Monitoring of Preoperative Chemotherapy for Locally Advanced Breast Cancer (2012) (8)
- Molecular determinants of post-mastectomy breast cancer recurrence (2018) (8)
- Abstract S3-5: Myelodysplatic syndrome and/or acute myelogenous leukemia (MDS and/or AML) after a breast cancer diagnosis: the National Comprehensive Cancer Network (NCCN) experience. (2012) (8)
- CALGB 60104: Adherence with adjuvant capecitabine among women age 65 and older with early stage breast cancer treated on CALGB 49907 (2008) (8)
- Updated results from the international phase III ALTTO trial (BIG 2-06/Alliance N063D). (2021) (7)
- How Do Older Adults Consider Age, Life Expectancy, Quality of Life, and Physician Recommendations When Making Cancer Screening Decisions? Results from a National Survey Using a Discrete Choice Experiment (2019) (7)
- Targeting Depressive Symptoms in Younger Breast Cancer Survivors: The Pathways to Wellness Randomized Controlled Trial of Mindfulness Meditation and Survivorship Education (2021) (7)
- Inflammatory cytokines and distant recurrence in HER2-negative early breast cancer (2022) (7)
- Breast cancer survivorship care plans: what are they covering and how well do they align with national guidelines? (2019) (7)
- Integrated Multiparametric Radiomics and Informatics System for Characterizing Breast Tumor Characteristics with the OncotypeDX Gene Assay (2020) (7)
- Does a Picture Make a Difference? Ultrasound Guidance in the Management of the Axilla After Neoadjuvant Chemotherapy. (2015) (7)
- Abstract S3-03: Ten year update of E1199: Phase III study of doxorubicin-cyclophosphamide followed by paclitaxel or docetaxel given every 3 weeks or weekly in patients with axillary node-positive or high-risk node-negative breast cancer (2015) (6)
- Abstract PD5-07: The impact of early lapatinib-induced rash on disease-free and overall survival in patients treated within the ALTTO phase III randomized trial (2016) (6)
- Abstract PD3-5: Whole exome sequencing (WES) of HER2+ metastatic breast cancer (MBC) from patients with or without prior trastuzumab (T): A correlative analysis of TBCRC003 (2015) (6)
- Surrogacy of Pathologic Complete Response in Trials of Neoadjuvant Therapy for Early Breast Cancer: Critical Analysis of Strengths, Weaknesses, and Misinterpretations. (2022) (6)
- Clinical evaluation of germline polymorphisms associated with capecitabine toxicity in breast cancer: TBCRC-015 (2020) (6)
- DNA methylation markers predict recurrence-free interval in triple-negative breast cancer (2020) (6)
- Multiomics in primary and metastatic breast tumors from the AURORA US network finds microenvironment and epigenetic drivers of metastasis (2022) (6)
- Ovarian Function Suppression: A Deeper Consideration of the Role in Early Breast Cancer and its Potential Impact on Patient Outcomes: A Consensus Statement from an International Expert Panel (2022) (6)
- Sociodemographic Factors Associated With Rapid Relapse in Triple-Negative Breast Cancer: A Multi-Institution Study. (2021) (6)
- Early operable breast cancer (2000) (6)
- Survivorship care visits in a high-risk population of breast cancer survivors (2018) (6)
- Abstract P2-13-02: Chemotherapy-related amenorrhea (CRA) after adjuvant trastuzumab emtansine (T-DM1) compared to paclitaxel in combination with trastuzumab (TH) (TBCRC033: ATEMPT trial) (2020) (6)
- SU11248 (sunitinib malate) therapy in patients with refractory metastatic breast cancer: preliminary safety and efficacy results from a phase II study (2006) (6)
- Breast cancer survivorship care beyond local and systemic therapy. (2019) (5)
- SWOG/Intergroup 9623: A phase III comparison of intensive sequential chemotherapy to high dose chemotherapy and autologous hematopoietic progenitor cell support (AHPCS) for primary breast cancer in women with >=4 involved axillary lymph nodes (2005) (5)
- Mobile Technology-Based (mLearning) Intervention to Enhance Breast Cancer Clinicians' Communication About Sexual Health: A Pilot Trial. (2021) (5)
- Examining Generalizability of Older Adults’ Preferences for Discussing Cessation of Screening Colonoscopies in Older Adults with Low Health Literacy (2019) (5)
- Complete radiologic response and long-term survival with use of systemic high-dose methotrexate for breast cancer-associated leptomeningeal disease. (2012) (5)
- Cyclin-Dependent Kinase 4/6 Inhibitors in the Treatment of Breast Cancer: More Breakthroughs and an Embarrassment of Riches. (2017) (5)
- Quality of life (QOL) among patients (pts) with HER2+ breast cancer (bc) treated with adjuvant lapatinib and/or trastuzumab in the ALTTO study (BIG 2-06, Alliance N063D). (2014) (5)
- Screening for Depression in Younger Breast Cancer Survivors: Outcomes From Use of the 9-item Patient Health Questionnaire (2021) (5)
- The ASCO Breast Cancer Registry pilot: Implementation of a multisite community practice registry and treatment plan/summary program. (2011) (5)
- Whole-exome sequencing (WES) of HER2+ metastatic breast cancer (MBC) from patients (pts) treated with prior trastuzumab (T): A correlative analysis of TBCRC003. (2014) (5)
- Abstract OT1-1-11: TBCRC 022: Phase II Trial of Neratinib for Patients with Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast cancer and Brain Metastases (2012) (5)
- Cardiac outcomes of subjects on adjuvant trastuzumab emtansine vs paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT) study (TBCRC033): a randomized controlled trial (2022) (5)
- Phase I study of continuous weekly dosing of dimethylamino benzoylphenylurea (BPU) in patients with solid tumours. (2007) (4)
- Black Race Is Associated with a Worse Outcome in Patients with Hormone Receptor Positive, HER2-Normal Breast Cancer Treated with Adjuvant Chemohormonal Therapy. (2009) (4)
- The role of EGFR amplification in trastuzumab resistance: A correlative analysis of TBCRC003. (2011) (4)
- TBCRC 019: An open-label, randomized, phase II trial of nanoparticle albumin-bound paclitaxel with or without the anti-death receptor 5 (DR5) monoclonal antibody tigatuzumab in patients with metastatic, triple-negative (ER, PR, and HER2-negative) breast cancer. (2011) (4)
- TBCRC 012: ABCDE, a phase II randomized study of adjuvant bevacizumab, metronomic chemotherapy (CM), diet and exercise after preoperative chemotherapy for breast cancer. (2010) (4)
- DNA methylation markers predict recurrence-free interval in triple-negative breast cancer (2020) (4)
- TBCRC 018: Phase II study of iniparib plus chemotherapy to treat triple-negative breast cancer (TNBC) central nervous system (CNS) metastases (mets). (2013) (4)
- MAF Amplification and Adjuvant Clodronate Outcomes in Early-Stage Breast Cancer in NSABP B-34 and Potential Impact on Clinical Practice (2021) (4)
- A rapid and sensitive method for determination of dimethyl benzoylphenyl urea in human plasma by using LC/MS/MS. (2003) (4)
- Current status of taxanes as adjuvant therapy for early-stage breast cancer. (2005) (4)
- Perceptions and needs of women with metastatic breast cancer: a focus on clinical trials. (2013) (4)
- CDK4/6 Inhibition in Early-Stage Breast Cancer: The New Standard? (2020) (4)
- Selection of Optimal Adjuvant Chemotherapy Regimens for Early Breast Cancer and Adjuvant Targeted Therapy for HER2-Positive Breast Cancers: An American Society of Clinical Oncology Guideline Adaptation of the Cancer Care Ontario Clinical Practice Guideline Summary. (2016) (4)
- Abstract GS3-08: Multiplatform analysis of matched primary and metastatic breast tumors from the AURORA US Network (2020) (4)
- Abstract OT1-03-21: PALLAS: PAlbociclib Collaborative Adjuvant Study: A randomized phase 3 trial of palbociclib with adjuvant endocrine therapy versus endocrine therapy alone for HR+/HER2- early breast cancer (2016) (4)
- Olaparib Use in Patients With Metastatic Breast Cancer Harboring Somatic BRCA1/2 Mutations or Mutations in Non-BRCA1/2, DNA Damage Repair Genes. (2021) (4)
- Abstract PD4-02: Safety and efficacy of a tucatinib-trastuzumab-capecitabine regimen for treatment of leptomeningeal metastasis (LM) in HER2-positive breast cancer: Results from TBCRC049, a phase 2 non-randomized study (2022) (4)
- Appendix B: Glossary (2008) (4)
- Adjuvant Lapatinib and/or Trastuzumab Treatment Optimisation: The ALTTO and Neo-ALTTO Trials (Principal Investigators, Martine Piccart-Gebhart and Edith A. Perez) (2011) (4)
- The use of anthracyclines and taxanes for adjuvant therapy of breast cancer (2001) (4)
- Preoperative Breast MRI for Newly Diagnosed Ductal Carcinoma in Situ: Imaging Features and Performance in a Multicenter Setting (ECOG-ACRIN E4112 Trial). (2021) (3)
- A method for determination of dimethyl benzoylphenyl urea (BPU) in human plasma by using LC/UV. (2004) (3)
- Facilitators and barriers to reducing chemotherapy for early-stage breast cancer: a qualitative analysis of interviews with patients and patient advocates (2022) (3)
- Improving detection methods for PIK3CA mutations in breast cancer using peripheral blood from patients with metastastic breast cancer (MBC). (2011) (3)
- Abstract GS6-03: Cisplatin versus doxorubicin/cyclophosphamide as neoadjuvant treatment in germline BRCA mutation carriers (BRCAcarriers) with HER2-negative breast cancer: Results from the INFORM trial (TBCRC 031) (2020) (3)
- Patient‐reported outcomes in the Translational Breast Cancer Research Consortium (2019) (3)
- Collecting tissue for research purposes: A survey of 16 institutions in the Translational Breast Cancer Research Consortium (TBCRC). (2011) (3)
- Abstract GS4-02: E2112: Randomized phase 3 trial of endocrine therapy plus entinostat/placebo in patients with hormone receptor-positive advanced breast cancer. A trial of the ECOG-ACRIN cancer research group (2021) (3)
- A multiparameter classifier to predict response to lapatinib plus trastuzumab (LT) without chemotherapy in HER2+ breast cancer (BC). (2020) (3)
- Abstract P2-09-12: Independent validation of the HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (2018) (3)
- Circulating tumor cell (CTC) and CA2729 as predictors of outcome in patients with metastatic breast cancer (MBC) in the prospective TBCRC 005 biomarker study. (2010) (3)
- Association between the 21-gene recurrence score and isolated locoregional recurrence in stage I-II, hormone receptor-positive breast cancer (2020) (3)
- Omics as useful tools in clinical practice: are we there yet? (2013) (3)
- Association of treatment-emergent symptoms identified by patient-reported outcomes with adjuvant endocrine therapy discontinuation (2022) (3)
- Investigating the impact of the COVID-19 pandemic on breast cancer clinicians’ communication about sexual health (2022) (3)
- Adjuvant systemic management of early stage carcinoma of the breast. (1999) (3)
- Association Between the 21-Gene Recurrence Score and Isolated Local-Regional Recurrence in Hormone Receptor-Positive Breast Cancer (2016) (3)
- Relationship Between Quality of Comorbid Condition Care and Costs for Cancer Survivors. (2016) (3)
- Reply to R. Bhargava et al and K. Lambein et al. (2014) (3)
- Abstract OT3-02-03: IMMUNe mOdulation in early stage estrogen receptor positive breast cancer treated with neoADjuvant Avelumab, Palbociclib, and Tamoxifen: The ImmunoADAPT study (NCT03573648) (2019) (3)
- Abstract PD10-02: Patient reported outcomes from the adjuvant trastuzumab emtansine (T-DM1) vs. paclitaxel + trastuzumab (TH) (ATEMPT) trial (TBCRC 033) (2020) (3)
- TBCRC026: Phase II clinical trial assessing the correlation of standardized uptake value (SUV) on positron emission tomography (PET) with pathological complete response (pCR) to pertuzumab and trastuzumab in patients with primary operable HER2-positive breast cancer. (2018) (3)
- Abstract OT3-05-08: PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase 3 trial of palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for HR+/HER2- early breast cancer (2018) (2)
- Phase I/II Trial of Partial Breast Irradiation With Concurrent Dose-Dense Doxorubicin and Cyclophosphamide (ddAC) Chemotherapy in Early Stage Breast Cancer: Report of Skin Toxicity and Cosmetic Outcome (2007) (2)
- TBCRC 018: Phase II study of iniparib plus chemotherapy to treat triple-negative breast cancer (TNBC) brain metastases (BM). (2011) (2)
- A randomized phase III post-operative trial of platinum-based chemotherapy (P) versus capecitabine (C) in patients (pts) with residual triple-negative breast cancer (TNBC) following neoadjuvant chemotherapy (NAC): ECOG-ACRIN EA1131 (2)
- 126TiP HER2CLIMB-02: Tucatinib or placebo with T-DM1 for unresectable locally-advanced or metastatic HER2+ breast cancer (2021) (2)
- A phase I study of diethylnorspermine (DENSPM) in previously treated patients with metastatic breast cancer (MBC) (2001) (2)
- Abstract PD2-12: Palbociclib in combination with fulvestrant or tamoxifen as treatment for hormone receptor positive (HR+) metastatic breast cancer (MBC) with prior chemotherapy for advanced disease (TBCRC 035) A phase II study with pharmacodynamics markers (2019) (2)
- Abstract P5-23-01: Clinical and biological characterization of male breast cancer (BC) EORTC 10085/TBCRC 029/BOOG 2013-02/BIG 2-07: Baseline results from the prospective registry (2018) (2)
- Abstract P3-12-02: Predictors of adherence to adjuvant endocrine therapy (ET) for early breast cancer (BC) in a prospective clinic-based cohort (2018) (2)
- Overcoming Barriers in Ductal Carcinoma In Situ Management: From Overtreatment to Optimal Treatment. (2021) (2)
- A Phase II study of the safety and efficacy of alpelisib or buparlisib plus letrozole in neoadjuvant treatment of postmenopausal women with HR+/HER2–, PIK3CA mutant or wild-type breast cancer. (2015) (2)
- Treatment of metastatic breast cancer: Chemotherapy (2014) (2)
- Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trial. (2023) (2)
- OT3-02-04: TBCRC 012: ABCDE, a Phase II Randomized Study of Adjuvant Bevacizumab, Metronomic Chemotherapy (CM), Diet and Exercise after Preoperative Chemotherapy for Breast Cancer. (2011) (2)
- P2-18-02: Cardiac Outcomes of Patients on Adjuvant Weekly Paclitaxel (T) and Trastuzumab (H) for Node Negative, HER2 Positive Breast Cancer (BCA). (2011) (2)
- Detection of circulating tumor cells in the cerebrospinal fluid: A new frontier (2012) (2)
- Late effects in a high-risk population of breast cancer survivors (2021) (2)
- Translational Breast Cancer Research Consortium (TBCRC) Patient Advocate Working Group (PAWG): An approach to research advocacy. (2011) (2)
- Abstract GS2-10: Targeting depressive symptoms in younger breast cancer survivors: A randomized controlled trial of mindfulness meditation and survivorship education (2021) (2)
- Cardiac Outcomes of Patients on Adjuvant Weekly Paclitaxel and Trastuzumab for Node Negative, HER2 Positive Breast Cancer (2017) (2)
- Adjuvant Abemaciclib Plus Endocrine Therapy in the Treatment of High-Risk Early Breast Cancer: ASCO Guideline Rapid Recommendation Update Q and A. (2022) (2)
- Relationship of circulating immune cells with lifestyle factors and cancer recurrence in early-stage breast cancer (2020) (2)
- LBA7DISEASE-FREE SURVIVAL (DFS) IN THE LAPATINIB ALONE ARM AND EXPANDED RESULTS OF THE PHASE III ALTTO TRIAL (BIG 2-06; NCCTG (ALLIANCE) N063D) IN THE ADJUVANT TREATMENT OF HER2-POSITIVE EARLY BREAST CANCER (EBC) (2014) (2)
- Making it work: Breast cancer survivorship care at Johns Hopkins. (2012) (2)
- Validation and implementation of a liquid chromatography/tandem mass spectrometry assay to quantitate dimethyl benzoylphenylurea (BPU) and its five metabolites in human plasma and urine for clinical pharmacology studies. (2005) (2)
- An estimation model for Oncotype DX recurrence score using routine histopathologic variables. (2014) (2)
- Development of an Automated Liquid Biopsy Assay for Methylated Markers in Advanced Breast Cancer (2022) (2)
- Implementing survivorship care planning in two contrasting health systems: lessons learned from a randomized controlled trial (2021) (2)
- Local failure and prognostic factors in ductal carcinoma in situ: concentration on recent publications (2003) (1)
- Detection of Cancer Specific Mutations in Plasma of Early Stage Breast Cancer Patients (2013) (1)
- The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group (2021) (1)
- Preventive care for breast cancer survivors versus controls: Changes between 1998 and 2002. (2008) (1)
- Abstract P3-09-04: AML and MDS after adjuvant chemotherapy: A population based study among older breast cancer patients (2015) (1)
- A prospective study of adjuvant anastrozole and gene promoter methylation in the contralateral breast of high-risk women (2008) (1)
- Abstract P1-13-05: The association between timing in adjuvant chemotherapy administration and overall survival for women with breast cancer within the National Comprehensive Cancer Network (NCCN) (2012) (1)
- Updated guideline on HER2 testing released by CAP/ASCO (2013) (1)
- Sensitivity for detecting PIK3CA mutations in early-stage breast cancer with droplet digital PCR. (2013) (1)
- Adjuvant palbociclib for ER+ breast cancer (PALLAS Trial (ABCSG-42/AFT-05/PrE0109/BIG-14-13): A preplanned analysis of the stage IIA cohort (2022) (1)
- TBCRC030: A randomized, phase II study of preoperative cisplatin versus paclitaxel in patients (pts) with BRCA1/2-proficient triple-negative breast cancer (TNBC)—Evaluating the homologous recombination deficiency (HRD) biomarker. (2014) (1)
- Abstract CT128: Palbociclib in combination with fulvestrant or tamoxifen as treatment for hormone receptor positive metastatic breast cancer with prior chemotherapy for advanced disease (TBCRC 035): A Phase II study with pharmacodynamic markers (2019) (1)
- Treatment discontinuation, patient-reported toxicities and quality-of-life by age following trastuzumab emtansine or paclitaxel/trastuzumab (ATEMPT) (2022) (1)
- American Society of Clinical Oncology/College ofAmerican Pathologists guideline recommendations forimmunohistochemical testing of estrogen andprogesterone receptors in breast cancer (2010) (1)
- Optimizing endocrine therapy for premenopausal and postmenopausal women with breast cancer. (2007) (1)
- Relationship between taxane-induced neuropathy and clinical outcomes after adjuvant chemotherapy. (2011) (1)
- Abstract P5-23-02: Quality of life (QoL) in male breast cancer (BC): Prospective study of the EORTC10085/TBCRC029/BIG2-07/NABCG International male BC program (2018) (1)
- Abstract OT-28-01: HER2CLIMB-02: A randomized, double-blind, phase 3 study of tucatinib or placebo with T-DM1 for unresectable locally-advanced or metastatic HER2+ breast cancer (2021) (1)
- Simplifying Survivorship Care Planning: A Randomized Controlled Trial Comparing 3 Care Plan Delivery Approaches. (2021) (1)
- Evaluation of tumor immune infiltrate as a determinant of response to neo-adjuvant lapatinib and trastuzumab (LT) in HER2-positive (+) breast cancer (BC). (2016) (1)
- Human epidermal growth factor receptor 2 testing recommendation. Authors' reply (2007) (1)
- Abstract OT-13-02: Bracelet-1 (pre0113): A study to assess overall response rate by inducing an inflammatory phenotype in metastatic breast cancer with the oncolytic reovirus pelareorep in combination with anti-PD-L1 avelumab and paclitaxel (2021) (1)
- Abstract PS4-03: An automated DNA methylation assay for monitoring treatment response in patients with metastatic breast cancer (2021) (1)
- 91 – Cancer of the Breast (2014) (1)
- Systemic therapy (2000) (1)
- Abstract P5-07-02: Factors associated with rapid relapse in triple negative breast cancer: A multi-institution study (2020) (1)
- Abstract OT2-01-01: Randomized, double-blind, phase 3 study of tucatinib or placebo in combination with T-DM1 for subjects with unresectable locally-advanced or metastatic HER2+ breast cancer (2020) (1)
- 353TiP HER2CLIMB-02: A randomized, double-blind, phase III study of tucatinib or placebo with T-DM1 for unresectable locally advanced or metastatic HER2+ breast cancer (2020) (1)
- Clinicopathologic and sociodemographic factors associated with late relapse triple negative breast cancer in a multivariable logistic model: A multi-institution cohort study (2023) (1)
- A phase II study evaluating efficacy of zoledronic acid in prevention of aromatase inhibitor (AI)-associated musculoskeletal symptoms: The ZAP trial. (2014) (1)
- Smart Search and Analysis of ASCO Abstracts: The 2003 ASCO Pilot Breast Cancer Information Exchange (BCIE) project. (2004) (1)
- Advanced machine learning informatics modeling using clinical and radiological imaging metrics for characterizing breast tumor characteristics with the OncotypeDX gene array (2018) (1)
- Anastrozole is safer and may be more effective than tamoxifen in postmenopausal women with early-stage breast cancer. (2004) (1)
- TBCRC 019: An open label, randomized, phase II trial of nanoparticle albumin-bound paclitaxel (nab-PAC) with or without the anti-death receptor 5 (DR5) monoclonal antibody tigatuzumab (TIG) in patients with metastatic triple negative breast cancer (TNBC). (2013) (1)
- Webinars as a tool for breast cancer survivorship education. (2013) (1)
- 191P Correlation of early change in standardized uptake value (SUV) on positron emission tomography (PET/CT) with recurrence-free survival (RFS) and overall survival (OS) in patients with primary operable HER2-positive breast cancer (TBCRC026) (2022) (1)
- NCCN Breast Cancer Version 3 . 2014 Clinical Practice Guidelines in Oncology (2014) (1)
- Survivorship care plans: Recommended vs delivered care. (2017) (1)
- Quality of care for comorbid conditions during the transition to survivorship. (2011) (1)
- Why is it so difficult to enroll patients in clinical trials (2014) (0)
- 158PDAdjuvant anti-HER2 therapy, treatment-induced amenorrhea (TIA) and survival in premenopausal patients (pts) with HER2-positive (HER2+) early breast cancer (EBC): Analysis from the ALTTO trial (BIG 2-06) (2017) (0)
- Table 3, Variability and reproducibility, Oncotype DX™ (2008) (0)
- Table 19, Clinical Utility, Oncotype DX™ (2008) (0)
- Breast cancer survivorship care beyond local and systemic therapy (2019) (0)
- Effect of renal function (RF) on outcomes in the adjuvant treatment of older women with breast cancer (>65 years): CALGB/CTSU 49907 (CC) ancillary data study. (2013) (0)
- Book Review: Progress in Anti-Cancer Chemotherapy, Volume II (2000) (0)
- Invasive Breast CancerPractice Guidelines in Oncology (2011) (0)
- Table 18, Clinical Validity, two-gene signature and H/I ratio assays (2008) (0)
- Pharmacologic intervention for primary and secondary prevention (0)
- A Phase II Study of the Polyamine Analog N,N- Diethylnorspermine (DENSpm) Daily for Five Days Every 21 Days in Patients with Previously Treated Metastatic Breast Cancer (2003) (0)
- Appendix D: Technologies (2008) (0)
- P2-09-07: Metabolic Response by FDG-PET in Patients (pts) Receiving Trastuzumab (T) and Lapatinib (L) for HER2+ Metastatic Breast Cancer (MBC): Correlative Analysis of TBCRC 003. (2011) (0)
- [Figure], Figure 1. Increasing complexity of information from genome to transcriptome and proteome: gene expression profiling focuses on the analysis of the transcriptome (2008) (0)
- Table 3, Evidence Table. Analytic validity, Oncotype DX™ (2008) (0)
- G472(P) The chameleon project: a children’s end of life care quality improvement project: preliminary results (2019) (0)
- Abstract P4-08-35: Young age at diagnosis is associated with worse prognosis in the luminal A breast cancer subtype. A retrospective institutional cohort study (2019) (0)
- Diabetes mellitus and survival after a diagnosis of breast cancer: A meta-analysis (2008) (0)
- The effect of modifications to clinical trial activities implemented during the COVID-19 pandemic on willingness to participate in clinical trials: The TBCRC 057 survey. (2022) (0)
- Table 5, Evidence Table. Critical appraisal of economic analyses of breast cancer gene expression testing (2008) (0)
- Table 4, Analytic validity, Oncotype DX™ (2008) (0)
- Abstract P6-01-04: The Hierarchy of Biomarkers (2023) (0)
- Appendix A: List of Acronyms (2008) (0)
- [Table], MAMMAPRINT®: the 70-gene signature (2008) (0)
- Appendix C: Description of Genes (2008) (0)
- Pregnancy and fertility with breast cancer: what are the options? (2009) (0)
- Reply to L. Del Mastro and A. Prat. (2017) (0)
- Abstract P4-08-09: DNA methylation markers predict recurrence-free interval in triple-negative breast cancer (2019) (0)
- SABCS: Using Molecular Assays for Breast Cancer in the Clinic (2012) (0)
- Abstract P4-10-02: Patient-reported outcomes in EA1131: A randomized phase III trial of platinum vs. capecitabine in patients with residual triple-negative breast cancer after neoadjuvant chemotherapy (2022) (0)
- Appendix G: Title Review Forms (2008) (0)
- Abstract P2-05-13: Negative progesterone receptor is associate early breast cancer relapse, even among good prognosis tumors (2017) (0)
- Abstract P6-05-54: "Clinical Trials are Space Travel": Moderators of Recurrence Stress among Breast Cancer Oncologists (2023) (0)
- Systemic therapy. (2000) (0)
- Facilitators and barriers to reducing chemotherapy for early-stage breast cancer: a qualitative analysis of interviews with patients and patient advocates (2022) (0)
- Abstract P2-08-15: Clinical, pathologic, and molecular associations of tumor mutational burden in metastatic breast cancer (2022) (0)
- Table 10, Reproducibility, two-gene signature and H/I ratio assay (2008) (0)
- Association of treatment-emergent symptoms identified by patient-reported outcomes with adjuvant endocrine therapy discontinuation (2022) (0)
- Two Phase 1/2 Trials of Partial Breast Irradiation (PBI) With Concurrent Chemotherapy Regimens: Late Toxicity, Cosmetic Outcome, and Disease Recurrence (2014) (0)
- Piloting survivorship care planning with the metastatic breast cancer patient. (2016) (0)
- Appendix I: Evidence Tables (2008) (0)
- A randomized intervention involving family to improve communication in breast cancer care (2021) (0)
- Phase I/II Trial of Partial Breast Irradiation with Concurrent Dose-dense Doxorubicin and Cyclophosphamide (ddAC) Chemotherapy in Early-stage Breast Cancer: Late Assessment of Toxicity, Cosmetic Outcome, and Disease Recurrence (2011) (0)
- Are Short-Term or Long-Term Recurrence Rates More Important in Breast Cancer Screening? (2008) (0)
- [Table], BCP - H/I assay: 2-gene signature and normalizing genes (2008) (0)
- Study participants' perceptions of the process and impact of receiving results of N9831. (2006) (0)
- Qualitative Analysis of Interviews with Patients on Facilitators and Barriers to Reducing Chemotherapy for Early Stage Breast Cancer (2021) (0)
- Abstract 18574: Functional Impairment of Human Resident Cardiac Stem Cells Contributes to Trastuzumab (Herceptin(R)) Cardiotoxicity (2010) (0)
- Reply to C. Murray et al and V. Martin et al. (2018) (0)
- MultiparametricMagnetic Resonance Imaging , Spectroscopy and Multinuclear ( 23 Na ) Imaging Monitoring of Preoperative Chemotherapy for Locally Advanced Breast Cancer (2010) (0)
- Table 13, Risk classification of Oncotype DX™ against the St. Gallen criteria (2008) (0)
- Table 21, Clinical Utility, two-gene signature and H/I ratio (2008) (0)
- Weight Gain after Hormone Receptor-Positive Breast Cancer (2022) (0)
- CLO22-033: Clinicopathologic and Sociodemographic Factors Associated With Late Relapse Triple Negative Breast Cancer (2022) (0)
- Table 9, Evidence Table. Clinical utility and validity, MammaPrint® (2008) (0)
- Multinuclear and Multiparametric MR imaging as an early treatment response biomarker for preoperative systemic therapy in breast cancer : Preliminary Results (2008) (0)
- Abstract P5-04-16: Association of circulating immune cells with lifestyle factors, and recurrence and mortality in patients with early stage breast cancer (2020) (0)
- Table 11, Evidence Table. Study population characteristics, H/I ratio (2008) (0)
- Cardiac outcomes of subjects on adjuvant trastuzumab emtansine vs paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT) study (TBCRC033): a randomized controlled trial (2022) (0)
- Antibody-Drug Conjugates in Breast Cancer: Searching for Magic Bullets. (2022) (0)
- Abstract P2-08-14: Dissecting the effect of hormone receptor (HR) status expression in patients (pts) with HER2-positive (HER2+) early breast cancer (EBC): Exploratory analysis from the ALTTO (BIG 2-06) trial (2019) (0)
- 767 poster PARTIAL BREAST IRRADIATION WITH CONCURRENT DOSE DENSE DOXORUBICIN & CYCLOPHOSPHAMIDE: LATE TOXICITY & RECURRENCE (2011) (0)
- Abstract P3-01-07: Phase II trial of palbociclib with fulvestrant in individuals with hormone receptor-positive, HER2-negative metastatic breast cancer with disease progression after palbociclib with an aromatase inhibitor (2023) (0)
- Systemic therapy. (2001) (0)
- Table 6, Successful assays, MammaPrint® (2008) (0)
- Abstract P3-04-01: Molecular determinants of post-mastectomy breast cancer recurrence (2018) (0)
- Table 12, Evidence Table. Analytic validity, H/I ratio (2008) (0)
- National Guidelines and Level of Evidence: Comments on Some of the New Recommendations in the American Society of Clinical Oncology and the College of American Pathologists Human Epidermal Growth Factor Receptor 2 Guidelines for Breast Cancer Reply (2015) (0)
- Abstract P6-03-07: An automated DNA methylation assay (QM-MSP) for rapid breast cancer diagnosis in underdeveloped countries (2018) (0)
- Outcomes from Two Phase I/II Trials of Partial-Breast Irradiation (PBI) and Concurrent Chemotherapy (2019) (0)
- Table 1, Description of the three gene expression profile assays (2008) (0)
- Inflammatory cytokines and distant recurrence in HER2-negative early breast cancer in the ECOG-ACRIN 5103 trial. (2021) (0)
- Abstract P2-02-01: Accurate identification of metastatic breast cancer using methylated gene markers in circulating free DNA in peripheral blood (2012) (0)
- THE BOTTOM LINE Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer : American Society of Clinical Oncology / College of American Pathologists Clinical Practice Guideline Focused Update Guideline Questions (2018) (0)
- JNCCN NCCN Task Force Report : Adjuvant Therapy for Breast Cancer — Clarification and Expansion of NCCN Clinical Practice Guidelines (2006) (0)
- Table 7, Reproducibility, MammaPrint® (2008) (0)
- The Olin/Muss article reviewed (2000) (0)
- Abstract P4-01-01: Circulating tumor cell (CTC) enumeration and HER2 assessment as predictors of breast cancer outcomes in the ALTTO (BIG 2-06, Alliance N063D) Trial (2014) (0)
- Abstract P1-04-01: Significance of circulating tumor cells in metastatic triple negative breast cancer: Results of an open label, randomized, phase II trial of nanoparticle albumin-bound paclitaxel with or without the anti-death receptor 5 tigatuzumab (TBCRC 019) (2013) (0)
- Abstract 1388: A novel Hyper-Methylation Outlier method for blood biomarker discovery (2019) (0)
- Abstract P5-12-04: A new method of data analysis to derive DNA methylation signatures that stratify risk of recurrence in triple negative breast cancer (2019) (0)
- Table 1, Evidence Table. Study design, Oncotype DX™ (2008) (0)
- A simple, validated model for identifying cases that are unlikely to benefit from the 21-gene recurrence score (RS) assay. (2014) (0)
- Translational Breast Cancer Research Consortium 022: Pre- and Post-operative Neratinib for HER2-positive Breast Cancer Brain Metastases (2020) (0)
- Table 8, Evidence Table. Analytic validity, MammaPrint® (2008) (0)
- Integrated Systems and Technologies Novel Methylated Biomarkers and a Robust Assay to Detect Circulating Tumor DNA in Metastatic Breast Cancer (2014) (0)
- Integrated Radiological Informatics System with comparison to Oncotype DX gene array (2018) (0)
- Outcomes with External Beam Partial Breast Irradiation and Concurrent Chemotherapy (PBICC) Compared to Whole Breast Irradiation and Sequential Chemotherapy (WBISC) in Triple Negative Breast Cancer (TNBC) Patients (2011) (0)
- Table 20, Comparison of economic studies (2008) (0)
- [Figure], Figure 3. Schematic model for microarray hybridizations. Panel A: two-color scheme design. Panel B: single-color design (2008) (0)
- Abstract P1-08-35: Stromal tumor infiltrating lymphocytes analysis by race and ethnicity in triple negative breast cancers from 2 phase III randomized adjuvant breast cancer trials: ECOG-ACRIN E2197 and E1199 (2022) (0)
- Abstract ES1-2: The Practical Use of Molecular Profiling: The View of a Medical Oncologist (2012) (0)
- Table 13, Evidence Table. Clinical utility and validity, H/I ratio (2008) (0)
- Outcomes of African American (AA) versus caucasian (CA) women with triple-negative (TN) breast cancer following preoperative anthracycline and taxane-based chemotherapy (2008) (0)
- Abstract PD11-06: PD11-06 Circulating tumor DNA association with residual cancer burden after neoadjuvant therapy in triple negative breast cancer in TBCRC 030 (2023) (0)
- Abstract GS1-07: Adjuvant palbociclib in HR+/HER2- early breast cancer: Final results from 5,760 patients in the randomized phase III PALLAS trial (2022) (0)
- why do few cancer patients enrol into clinical trials (2018) (0)
- Intrinsic radiomics phenotypes of DCI from breast DCE-MRI: demonstrating feasibility in interim analysis of the ECOG-ACRIN E4112 trial (2021) (0)
- Increased African-American Enrollment in Breast Cancer Clinical Trials: A Single-Institution Experience (2014) (0)
- [Table], ONCOTYPE™: the 21-gene signature (2008) (0)
- Academic and community physician perspectives on breast cancer biomarker use in clinical trials. (2022) (0)
- Table 4, Evidence Table. Clinical utility and validity, Oncotype DX™ (2008) (0)
- The Eneman/Wood/Muss article reviewed (2004) (0)
- Current endocrine therapy options for postmenopausal women with early-stage hormone receptor-positive breast cancer (2005) (0)
- Phase I/II Trial of Partial Breast Irradiation (PBI) With Various Concurrent Chemotherapy Regimens: Assessment of Skin Toxicity, Cosmetic Outcomes, and Disease Recurrence (2012) (0)
- Peeling back the curtain: The impact of patient and provider race on clinical trial enrollment. (2022) (0)
- Abstract P4-01-16: Detection of plasma tumor DNA (ptDNA) in patients with hormone receptor-positive HER2-negative (HR+HER2-) early breast cancer (EBC) in clinical remission (2019) (0)
- Table 2, Successful assays, Oncotype DX™ (2008) (0)
- Abstract PS9-14: Feasibility of monitoring symptoms during endocrine therapy with patient reported outcomes collected via smart phone app (2021) (0)
- Table 14, Risk classification of Oncotype DX™ against the 2004 NCCN guidelines (2008) (0)
- Abstract PD7-03: Translational Breast Cancer Research Consortium Trial 022: Neratinib and Trastuzumab-Emtansine for HER2+ Breast Cancer Brain Metastases (BCBM) (2023) (0)
- Abstract OT3-15-01: TBCRC-053: P-RAD: A Randomized Study of Preoperative Chemotherapy, Pembrolizumab and No, Low or High Dose RADiation in Node-Positive, HER2-Negative Breast Cancer (2023) (0)
- Table 12, Clinical validity, Oncotype DX™ (2008) (0)
- Obesity at diagnosis and after treatment in breast cancer survivors and risk of neuropathy. (2018) (0)
- Abstract P4-02-09: Evaluation of the Automated Liquid Biopsy-Breast Cancer Methylation (LBx-BCM) Cartridge Assay for Predicting Early Disease Progression and Survival: TBCRC-005 Prospective Trial (2023) (0)
- Table 10, Evidence Table. Study design, H/I ratio (2008) (0)
- Evaluation of a Liquid Biopsy-Breast Cancer Methylation (LBx-BCM) Cartridge Assay for Predicting Early Disease Progression and Survival: TBCRC 005 Prospective Trial. (2022) (0)
- Phase I/II trial of partial breast irradiation (PBI) with various concurrent chemotherapy regimens. (2012) (0)
- Physician Perspectives on Reducing Curative Cancer Treatment Intensity for Populations Underrepresented in Clinical Trials (2022) (0)
- Cancer susceptibility genes and their potential implication regarding systemic therapy for early‐stage breast cancer (2016) (0)
- Assays of circulating tumor cells and outcome in the triple-negative breast cancer trial TBCRC001. (2009) (0)
- Abstract P6-08-07: Reasons for Reduced Willingness to Participate in Clinical Trials During the COVID-19 Pandemic: The Translational Breast Cancer Research Consortium (TBCRC) 057 Survey (2023) (0)
- Simplifying survivorship care planning: A randomized controlled trial comparing three care plan delivery approaches. (2021) (0)
- “It sounds very negative”: Patient perspectives on de-escalation of treatment concept and language. (2022) (0)
- Comparing Three Ways to Help Cancer Survivors Plan for Follow-Up Care (2022) (0)
- Table 16, Clinical Validity, MammaPrint® and 70-gene signature (2008) (0)
- Evaluating potential overuse of surveillance care in cancer survivors (2022) (0)
- Table 7, Evidence Table. Study population characteristics, MammaPrintsup® (2008) (0)
- Abstract P2-11-05: Effects of Intrinsic Subtypes and 21-gene Assay on the Early and Late Recurrence Risks in Patients with Early Stage HER2+ Breast Cancer: An Analysis of the North Central Cancer Treatment Group (NCCTG) N9831 (Alliance) Trial (2023) (0)
- The Mina/Sledge article reviewed (2006) (0)
- International disparity in breast cancer outcomes: the time to close the gap is now. (2010) (0)
- Older adults' perspectives on incorporating life expectancy in cancer screening. (2016) (0)
- New data on adjuvant therapy for breast cancer (1999) (0)
- Engaging care partners in breast cancer care and communication. (2019) (0)
- 366 Evaluation of Gefitinib biological effects in patients with solid tumors amenable to sequential biopsies (2004) (0)
- Table 11, RT-PCR vs IHC comparison assays, two-gene signature and H/I ratio assays (2008) (0)
- Abstract P6-10-05: TBCRC 040: Pathologic response evaluation and detection in circulating tumor DNA (PREDICT DNA): Initial results piloting a tissue-biopsy independent method of identifying and monitoring tumor-specific mutations in early stage breast cancer (2020) (0)
- Abstract PD18-01: Adjuvant Trastuzumab Emtansine Versus Paclitaxel plus Trastuzumab for Stage I HER2+ Breast Cancer: 5-year results and correlative analyses from ATEMPT (TBCRC033) (2023) (0)
- CTNI-02. TBCRC049: A PHASE II STUDY TO ASSESS THE SAFETY AND EFFICACY OF THE COMBINATION OF TUCATINIB, TRASTUZUMAB AND CAPECITABINE FOR THE TREATMENT OF LEPTOMENINGEAL METASTASIS IN HER2 POSITIVE BR1AST CANCER (2020) (0)
- Table 6, Evidence Table. Study design, MammaPrint® (2008) (0)
- Abstract OT1-02-03: TBCRC 044: A randomized phase II study of pembrolizumab in combination with carboplatin versus carboplatin alone in breast cancer patients with chest wall disease (2018) (0)
- Roundtable discussion: Current standard of care for adjuvant hormonal treatment of breast cancer (2005) (0)
- Abstract PD18-02: Adjuvant Paclitaxel and Trastuzumab Trial (APT) for Node-Negative, Human Epidermal Growth Factor Receptor 2–Positive (HER2+) Breast Cancer: final 10-year analysis (2023) (0)
- Erratum: Systemic therapy (Current Opinion in Oncology (2001) 13 (436-449)) (2002) (0)
- Physician perspectives on extrapolating data from trials testing less-intense treatment to underrepresented populations. (2022) (0)
- Appendix A: Technical Experts and Peer Reviewers (2008) (0)
- Abstract PD3-10: Patient perspectives on chemotherapy de-escalation: “Don’t de-escalate! I don’t want to die!” (2021) (0)
- Is care coordination associated with improved care quality for comorbid conditions in cancer survivors (2012) (0)
- Abstract P4-12-01: Adherence with adjuvant endocrine therapy with or without Palbociclib in the PALLAS trial (2022) (0)
- DNA methylation in serum as an independent marker of outcome and treatment response in TBCRC 005: A prospective study in metastatic breast cancer (MBC) patients. (2015) (0)
- Abstract P2-06-01: cMethDNA is a quantitative circulating methylated DNA assay for detection of metastatic breast cancer and for monitoring response to therapy (2013) (0)
- Association between the 21-gene recurrence score and isolated locoregional recurrence in stage I-II, hormone receptor-positive breast cancer (2020) (0)
- Appendix H: Excluded Articles (2008) (0)
- Trial in progress: A phase 1b/2 study of the PARP inhibitor niraparib in combination with trastuzumab in patients with metastatic HER2+ breast cancer (TBCRC 050). (2021) (0)
- The authors respond [2] (2007) (0)
- In Reply. (2019) (0)
- Table 2, Evidence Table. Study population characteristics, Oncotype DX™ (2008) (0)
- Molecular determinants of post-mastectomy breast cancer recurrence (2018) (0)
- Oncologist-Reported Barriers and Facilitators to Enrolling Patients in Optimization Trials That Test Less Intense Cancer Treatment (2022) (0)
- 750 poster COSMETIC OUTCOME AFTER PARTIAL BREAST IRRADIATION WITH CONCURRENT CHEMOTHERAPY IN EARLY-STAGE BREAST CANCER (2011) (0)
- Tailoring the optimal duration of the extended adjuvant endocrine therapy in patients with early-stage breast cancer. A systematic review and meta-analysis of randomized clinical trials (2023) (0)
- Appendix F: Detailed Electronic Database Search Strategies (2008) (0)
- Reply to T. Shimoi et al and Y. Shimanuki et al. (2021) (0)
- 67TiP HER2CLIMB-02: A randomized, double-blind, phase III study of tucatinib or placebo with T-DM1 for unresectable locally-advanced or metastatic HER2+ breast cancer (2020) (0)
- Table 17, MammaPrint® compared with traditional composite risk markers (2008) (0)
- Abstract PD6-11: PD6-11 Evaluation of the Sensitivity to Endocrine Therapy Index (SET2,3) in Early Male Breast Cancer: Results from an analysis in the EORTC 10085/TBCRC/BIG/NCTN International Male Breast Cancer Program (2023) (0)
- Commentary (Carraway/Wolff): Selecting Adjuvant Endocrine Therapy for Breast Cancer (2004) (0)
- Abstract P6-12-21: Breast cancer survivors undergoing survivorship visits at Johns Hopkins are a high-risk population (2018) (0)
- Improving biobehavioral health in younger breast cancer survivors: Pathways to Wellness trial secondary outcomes. (2022) (0)
- Still Refining Adjuvant Endocrine Therapy in Premenopausal Women: Not Too Much, Not Too Little. (2016) (0)
- Table 8, Analytic validity, MammaPrint® (2008) (0)
- Table 9, Successful assays, two-gene signature and H/I ratio assays (2008) (0)
- Commentary (Wolff/Davidson): Twenty Years of Systemic Therapy for Breast Cancer (2006) (0)
- Abstract P3-08-05: Chemotherapy-related amenorrhea on adjuvant paclitaxel-trastuzumab (APT trial) (2013) (0)
- Table 5, RT-PCR vs IHC comparison assays, Oncotype DX™ (2008) (0)
- Racial and ethnic disparities in mortality among breast cancer survivors after a second malignancy. (2022) (0)
- Abstract P4-16-09: Effect of simvastatin on cardiac strain in breast cancer patients receiving anthracycline therapy (2019) (0)
- Circulating tumor DNA association with residual cancer burden after neoadjuvant chemotherapy in triple-negative breast cancer in TBCRC 030 (2023) (0)
- Table 15, Risk classification of Oncotype DX™ against the Adjuvant! guidelines (2008) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Antonio C. Wolff?
Antonio C. Wolff is affiliated with the following schools:
